Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points

Author(s): Tanveer A. Wani, Abdus Samad, P. L. Sharma, Monika Tandon, J. K. Paliwal

Journal Name: Letters in Drug Design & Discovery

Volume 6 , Issue 8 , 2009

Become EABM
Become Reviewer


This was an open label, balanced, randomized, three-treatment, three-sequence, three period, single-dose, crossover bioavailability study in which healthy adults (age18-45 years) were randomized to receive sustained release tablets of Voveran SR (Product R), Nac SR (Product A) and Reactin SR (Product B) each containing diclofenac sodium 100 mg with at least 3 days wash out between treatments. Eighteen healthy, adult, male, human subjects who met the inclusion and exclusion criteria as described in the protocol were enrolled in the study. Pharmacokinetic parameters like Tmax, Cmax, AUC 0-t, AUC 0-∞, AUC0-t/ AUC 0-∞, Kel, T1/2 & MRT were calculated for the Products A, B and R. Product A fared better than product B in some bioequivalence parameters. However, both the test products (Nac SR and Reactin SR) were not bioequivalent to product R (Voveran SR).

Keywords: Diclofenac Sodium, Sustained Release, Cmax, Tmax, AUC0-t, AUC0-inf, Bioequivalence

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [629 - 636]
Pages: 8
DOI: 10.2174/157018009789353518
Price: $65

Article Metrics

PDF: 1